Individuals’ metabolomic marker profiles may predict the onset of inflammatory bowel disease a decade in advance, underlining ...

Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.

Crohn's disease, a debilitating inflammatory bowel disease, has many known contributing factors, including bacterial changes in the microbiome that foster an inflammatory environment.

The risk for both self-reported and symptomatic flare in inflammatory bowel disease is associated with psychosocial factors, ...

Drinking two small glasses of cherry juice a day may reduce gut inflammation and boost quality of life in bowel disease ...

Up to 40% of patients with inflammatory bowel disease (IBD) experience extraintestinal manifestations (EIMs), with the ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

A new study published in BMC Gastroenterology identified that patients with inflammatory bowel disease (IBD), such as Crohn's ...

An international team led by researchers at the University of Toronto has found a compound in ginger, called furanodienone ...

Tampa Bay Lightning forward Michael Eyssimont was diagnosed with Crohn's disease eight years ago at the age of 21. Since then ...

Ensho Therapeutics has presented additional data supporting NSHO-101, also referred to as EA1080, as an oral one-time-a-day ...